Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Working Capital Changes (2016 - 2024)

Protalix BioTherapeutics has reported Other Working Capital Changes over the past 15 years, most recently at $252062.0 for Q4 2024.

  • Quarterly results put Other Working Capital Changes at $252062.0 for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $252062.0 (up 101.91% YoY), and the annual figure for FY2024 was $252062.0, up 101.91%.
  • Other Working Capital Changes for Q4 2024 was $252062.0 at Protalix BioTherapeutics, down from $1.7 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for PLX hit a ceiling of $12.3 million in Q2 2021 and a floor of -$25.7 million in Q4 2020.
  • Median Other Working Capital Changes over the past 5 years was -$192500.0 (2020), compared with a mean of -$1.3 million.
  • Biggest five-year swings in Other Working Capital Changes: tumbled 14850.0% in 2020 and later surged 14394.19% in 2021.
  • Protalix BioTherapeutics' Other Working Capital Changes stood at -$25.7 million in 2020, then soared by 97.22% to -$715000.0 in 2021, then plummeted by 125.87% to -$1.6 million in 2022, then crashed by 630.03% to -$11.8 million in 2023, then skyrocketed by 102.14% to $252062.0 in 2024.
  • The last three reported values for Other Working Capital Changes were $252062.0 (Q4 2024), $1.7 million (Q2 2024), and $11.0 million (Q1 2024) per Business Quant data.